Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5284952
Max Phase: Preclinical
Molecular Formula: C84H145N18O16+
Molecular Weight: 1663.19
Associated Items:
ID: ALA5284952
Max Phase: Preclinical
Molecular Formula: C84H145N18O16+
Molecular Weight: 1663.19
Associated Items:
Canonical SMILES: CC[C@](C)(NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C(C)(C)NC(=O)[C@@H]1CCCCN1C(=O)C(C)(C)NC(=O)C(C)(C)NC(=O)CNC(=O)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@](C)(CC)NC(=O)[C@](C)(CC)NC(=O)[C@@H]1CCCCN1C(=O)C(C)(C)NC(=O)[C@@H]1CCCCN1C(C)=O)C(=O)N[C@@H](CC(C)C)CN1CCC[N+]2=C1CCC2
Standard InChI: InChI=1S/C84H144N18O16/c1-23-82(20,73(114)88-56(46-51(4)5)50-99-42-33-41-98-40-32-37-64(98)99)94-67(108)58(48-53(8)9)89-65(106)54(10)87-71(112)78(12,13)92-69(110)60-35-27-30-44-101(60)77(118)81(18,19)96-72(113)79(14,15)91-63(105)49-86-62(104)38-39-85-66(107)57(47-52(6)7)90-74(115)83(21,24-2)97-75(116)84(22,25-3)95-70(111)61-36-28-31-45-102(61)76(117)80(16,17)93-68(109)59-34-26-29-43-100(59)55(11)103/h51-54,56-61H,23-50H2,1-22H3,(H12-,85,86,87,88,89,90,91,92,93,94,95,96,97,104,105,106,107,108,109,110,111,112,113,114,115,116)/p+1/t54-,56-,57-,58-,59-,60-,61-,82-,83-,84-/m0/s1
Standard InChI Key: ZMWAWXUEXSENJI-XTLFDEQMSA-O
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1663.19 | Molecular Weight (Monoisotopic): 1662.1080 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Patel BA, D'Amico TL, Blagg BSJ.. (2020) Natural products and other inhibitors of F1FO ATP synthase., 207 [PMID:32942072] [10.1016/j.ejmech.2020.112779] |
Source(1):